Table I.
Clinicopathological and experimental data obtained from patients with NSCLC from La Paz University Hospital
| miR-7 methylation | miR-7 expression | MAFG expression | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Histology | Sex | Stage | Chemotherapy | ATT (%) | T (%) | ATT (2−ΔCt) | T (2−ΔCt) | ATT (2−ΔCt) | T (2−ΔCt) | apMAFG3F (% of PC) | apMAFG6F (% of PC) | apMAFG11F (% of PC) | Status | OS, days |
| 1 | Adenocarcinoma | Female | IA | No | 58.49 | NA | 0.50 | 0.19 | 0.62 | 0.43 | 70.81 | NA | 79.26 | Alive | 2220 |
| 2 | Epidermoid | Male | IB | No | 5.63 | 5.35 | 1.71 | 2.61 | 0.65 | 0.53 | 84.14 | 90.93 | 27.83 | Exitus | 1022 |
| 3 | Adenocarcinoma | Male | IB | No | 14.98 | 13.12 | 1.16 | 0.31 | 0.59 | 0.28 | NA | 77.11 | NA | Exitus | 3 |
| 4 | Adenocarcinoma | Male | NA | No | 12.47 | 26.06 | 1.11 | 0.51 | 0.43 | 4.37 | 90.61 | 91.08 | 87.18 | Exitus | 626 |
| 5 | Large Cell | Male | IIB | No | 9.20 | 12.69 | 0.80 | 0.34 | 0.28 | 0.29 | 44.69 | 25.55 | 21.72 | Exitus | 62 |
| 6 | Adenocarcinoma | Male | IIIA | Other | 7.28 | 3.74 | 2.33 | 0.38 | 0.31 | 2.12 | 84.77 | 79.60 | 40.41 | Exitus | 228 |
| 7 | Epidermoid | Female | IIIB | CDDP + Other | 8.47 | 5.69 | 1.65 | 1.77 | 0.58 | 0.05 | 67.48 | 87.21 | 22.58 | Exitus | 109 |
| 8 | Adenocarcinoma | Female | IIA | CDDP + Other | 8.37 | 28.94 | 0.70 | 2.42 | 0.91 | 0.13 | 77.15 | 79.55 | 59.50 | Alive | 2260 |
| 9 | Epidermoid | Male | IB | No | 9.41 | 8.09 | 1.07 | 1.17 | 5.59 | 0.29 | 74.31 | 73.12 | NA | Alive | 1853 |
| 10 | Adenocarcinoma | Male | IA | No | 8.19 | 38.79 | 1.00 | 0.09 | 1.00 | 0.04 | 75.39 | 69.14 | 74.06 | Exitus | 216 |
| 11 | Adenocarcinoma | Female | IIIA | CBDCA + Other | 6.51 | 6.08 | 0.99 | 5.83 | 1.91 | 0.20 | 53.02 | 35.66 | 68.15 | Alive | 2192 |
| 12 | Epidermoid | Male | IB | CDDP + Other | 7.59 | 30.28 | 0.92 | 0.75 | 2.24 | 0.81 | 77.27 | 92.45 | NA | Alive | 2341 |
| 13 | Epidermoid | Male | IIA | No | 12.44 | NA | 0.77 | 1.51 | 0.70 | 0.09 | 88.89 | 84.07 | 75.52 | Exitus | 289 |
| 14 | Epidermoid | Male | IIA | No | 12.66 | 10.98 | 2.21 | 2.07 | 0.73 | 0.84 | 90.76 | 96.88 | NA | NA | 109 |
| 15 | Adenocarcinoma | Female | IIIA | CDDP + Other | 4.72 | 3.57 | 0.73 | 0.32 | 0.76 | 0.49 | NA | NA | NA | Alive | 2228 |
| 16 | Adenocarcinoma | Male | IIB | Other | 35.35 | 10.00 | 0.80 | 0.31 | 1.03 | 0.78 | 75.77 | 95.65 | 94.51 | Exitus | 888 |
| 17 | Epidermoid | Male | IIB | CBDCA + Other | 8.24 | 53.19 | 1.35 | 1.05 | 0.57 | 0.03 | 74.61 | 28.90 | 44.30 | Exitus | 259 |
| 18 | Adenocarcinoma | Female | IB | CDDP + Other | 10.29 | 9.42 | 1.19 | 2.86 | 0.38 | 1.52 | 95.72 | 93.75 | 87.23 | Exitus | 936 |
| 19 | Epidermoid | Male | IIB | CDDP + Other | 13.67 | 9.52 | 1.50 | 2.87 | 0.99 | 0.50 | NA | NA | NA | Exitus | 1224 |
| 20 | Epidermoid | Male | IIIB | CBDCA + Other | 4.06 | 13.45 | 0.80 | 1.33 | 0.22 | 0.43 | 85.99 | NA | 2.24 | Exitus | 603 |
| 21 | Adenocarcinoma | Male | IIIA | CDDP + Other | 9.55 | 63.07 | 1.14 | 0.65 | 1.11 | 2.57 | NA | 67.21 | 71.08 | NA | 421 |
| 22 | Adenocarcinoma | Female | IIB | CDDP + Other | 4.43 | 6.84 | 0.50 | 2.07 | 0.26 | 2.35 | 80.30 | 92.55 | 78.10 | NA | 184 |
Abbreviations: ATT: adjacent tumor tissue; CBDCA: carboplatin; CDDP: cisplatin; NA: not available; NSCLC: non-small cell lung cancer; OS, Overall Survival; % of PC: % of Positive Cells; T: tumor.